The First Hospital of Jilin University

Dr. Li Wei is a nationally recognized neurologist with over 25 years of clinical and academic experience. He leads the Cerebrovascular Intervention Unit at Jilin University First Hospital and serves as a principal investigator in multiple NIH- and NSFC-funded trials on acute ischemic stroke thrombectomy and neuroprotective strategies. Dr. Li pioneered the hospital’s comprehensive stroke center certification by the Chinese Stroke Association in 2018. He regularly lectures at international conferences including the World Stroke Congress and ESO, and has authored over 90 peer-reviewed publications in journals such as Stroke and The Lancet Neurology. His patient-centered approach emphasizes rapid diagnosis, evidence-based intervention, and long-term cognitive rehabilitation. Dr. Li mentors residents and fellows in advanced neuroimaging interpretation and tele-neurology implementation across rural Jilin Province.

Dr. Zhang Min is a leading cardiothoracic surgeon specializing in high-precision, minimally invasive techniques for complex coronary and valvular disease. She established the hospital’s robotic-assisted cardiac surgery program in 2017—the first in Northeast China—and has performed over 1,200 robotic procedures. Dr. Zhang co-developed the 'Jilin Hybrid Revascularization Protocol', now adopted by 14 provincial hospitals. Her research focuses on perioperative myocardial protection and AI-driven surgical outcome prediction. She serves on the Editorial Board of the Asian Journal of Cardiovascular Surgery and chairs the Northeast Regional Committee of the Chinese Society for Cardiovascular Surgery. Known for her meticulous technique and compassionate communication, Dr. Zhang routinely conducts preoperative counseling in Mandarin, English, and Korean to serve diverse regional patients.

Dr. Chen Yuhua is an internationally acclaimed oncologist pioneering biomarker-guided treatment for lung, gastric, and liver cancers. As Principal Investigator of 12 national multicenter trials—including the landmark CHINA-IO phase III study—she helped establish China’s first NMPA-approved ctDNA monitoring protocol for early relapse detection. Dr. Chen founded the hospital’s Molecular Tumor Board and integrated genomic profiling into routine care since 2016. Her translational lab discovered two novel resistance mechanisms in EGFR-mutant NSCLC, published in Nature Medicine and Cell. She actively advocates for equitable access to targeted therapies across Northeast China and trains oncologists from 30+ grassroots hospitals annually. Patients consistently commend her clarity in explaining complex genomic reports and empathetic support through treatment decision-making.

Dr. Wang Jian is a top-tier spinal surgeon renowned for innovative solutions in geriatric spine deformity correction and osteoporosis-related instability. He developed the 'Jilin Osteo-Spine Stabilization System'—a biomechanically optimized pedicle screw design now used in over 60 hospitals nationwide. His team performs more than 400 complex spine surgeries annually, including vertebral column resections and multi-level osteotomies for severe kyphoscoliosis. Dr. Wang integrates intraoperative navigation, neuromonitoring, and frailty assessment to minimize complications in elderly patients averaging 72 years old. He chairs the Chinese Orthopaedic Association’s Spine Geriatrics Subcommittee and co-authored the 2023 national consensus on surgical management of osteoporotic spinal fractures. Fluent in English and Japanese, he frequently hosts international observers and delivers workshops on safe cement-augmented fixation techniques.

Dr. Liu Fang is a distinguished pediatrician and neonatologist whose leadership transformed the NICU at Jilin University First Hospital into a Level IV Regional Perinatal Center—the highest designation in China. She spearheaded the implementation of whole-exome sequencing for critically ill newborns, reducing diagnostic odysseys by 68% and enabling targeted therapy for rare metabolic diseases. Dr. Liu co-founded the Northeast Pediatric Genetic Consortium and developed standardized developmental surveillance tools adapted for rural communities. Her longitudinal cohort study on preterm neurodevelopment outcomes has informed national guidelines since 2020. A passionate educator, she supervises over 50 pediatric residents yearly and created the hospital’s award-winning 'Family Integrated Care' model, empowering parents as essential NICU care partners. Her calm demeanor and scientific rigor bring reassurance to families facing high-stakes diagnoses.

Dr. Sun Tao is a world-class gastroenterologist specializing in endoscopic eradication of early gastrointestinal cancers and refractory inflammatory bowel disease. He performed Northeast China’s first peroral cholangioscopy-guided lithotripsy and pioneered fecal microbiota transplantation (FMT) protocols for steroid-dependent ulcerative colitis—achieving 72% remission at one year. His endoscopy training center certifies over 200 physicians annually in ESD, POEM, and ERCP. Dr. Sun leads the hospital’s Gut Microbiome Translational Lab, identifying predictive microbial signatures for IBD flare-ups using metagenomic sequencing. He serves on the editorial board of Gut and co-chairs the Asia-Pacific Working Group on Endoscopic Submucosal Dissection. Patients value his thorough pre-procedure consultations, real-time procedural explanations via endoscopic video feed, and personalized dietary and psychosocial support plans.

The Department of Cardiology at Jilin University First Hospital is a national key clinical specialty with over 60 years of history. It integrates clinical care, scientific research, and teaching, operating one of Northeast China's largest cardiac catheterization laboratories and a dedicated arrhythmia center. The department specializes in minimally invasive interventions, structural heart disease correction, and advanced heart failure management. Its multidisciplinary team includes 12 senior cardiologists certified by the American College of Cardiology and European Society of Cardiology. The department actively participates in national multicenter trials and has published over 200 peer-reviewed papers in high-impact journals. With round-the-clock STEMI response capability and a dedicated cardiac ICU, it delivers rapid, evidence-based care for complex cardiovascular conditions across all age groups.

Renowned as a national neurosurgical training base and key discipline of Jilin Province, this department excels in treating complex brain and spinal disorders using cutting-edge techniques. It houses a dedicated intraoperative MRI suite, neuronavigation platform, and robotic-assisted surgery system. The team performs over 1,800 craniotomies annually—including awake craniotomies for glioma resection—and leads regional stroke and traumatic brain injury networks. Research focuses on glioblastoma molecular profiling, neuroendovascular therapeutics, and neural regeneration. Faculty hold leadership roles in the Chinese Neurosurgical Society and regularly host international workshops. With strict quality control protocols and real-time neuromonitoring, outcomes consistently exceed national benchmarks for both elective and emergency neurosurgical interventions.

As a National Clinical Key Specialty and WHO Collaborating Center for Hematology, this department pioneers precision diagnostics and targeted therapies for hematologic malignancies and rare blood disorders. It operates Northeast China’s first accredited CAR-T cell therapy manufacturing facility and a comprehensive bone marrow transplant unit with over 300 annual allogeneic transplants. The team utilizes next-generation sequencing, flow cytometry, and digital PCR to guide individualized treatment plans. Clinical trials include novel bispecific antibodies, epigenetic modulators, and MRD-guided consolidation strategies. The department also manages China’s largest registry for immune thrombocytopenia and hereditary hemoglobinopathies. With integrated psychosocial support and long-term survivorship programs, it ensures holistic, patient-centered care from diagnosis through remission.

This nationally recognized orthopedic center combines biomechanical engineering expertise with clinical excellence in joint reconstruction, spine surgery, sports medicine, and trauma care. It serves as the Northeast Regional Trauma Center and hosts a state-of-the-art gait analysis laboratory and 3D-printing surgical planning suite. The department performs over 4,500 joint replacements yearly—including robotic-arm assisted total knee arthroplasty—and leads national guidelines for osteoporotic fracture prevention. Its spine division specializes in minimally invasive deformity correction and artificial disc replacement. Research collaborations with Jilin University’s School of Materials Science have yielded FDA-cleared bioactive implants. Multidisciplinary rehabilitation pathways, same-day discharge protocols, and AI-powered post-op monitoring ensure accelerated functional recovery and reduced complication rates.

A National Key Clinical Discipline and designated National Digestive Disease Clinical Research Center, this department delivers comprehensive care for inflammatory bowel disease, hepatobiliary malignancies, pancreatic disorders, and early gastrointestinal cancers. Its endoscopy center performs over 65,000 procedures annually—including confocal laser endomicroscopy, ERCP with cholangioscopy, and submucosal tunneling dissection—and maintains the highest adenoma detection rate in Northeast China. The liver transplantation program, launched in 2010, has achieved >90% 1-year graft survival. The department co-leads the China IBD Consortium and developed the nationally adopted 'JLU-GI Risk Stratification Model' for predicting Crohn’s disease progression. With integrated pathology, radiology, and nutrition support, it offers seamless, pathway-driven care across the full GI disease spectrum.

Designated as a National Clinical Key Specialty and National Respiratory Disease Clinical Research Center, this department provides advanced diagnostics and therapeutics for chronic airway diseases, interstitial lung disease, pulmonary hypertension, and critical respiratory failure. It operates one of China’s largest extracorporeal membrane oxygenation (ECMO) programs for refractory ARDS and pioneered the use of adaptive servo-ventilation for obesity-hypoventilation syndrome. The department’s interstitial lung disease clinic integrates high-resolution CT radiomics, bronchoalveolar lavage proteomics, and genetic testing to refine idiopathic pulmonary fibrosis classification. Its COPD management program reduced hospital readmissions by 42% through AI-driven remote monitoring and personalized pulmonary rehabilitation. Faculty contribute to GOLD and ATS guidelines and lead multiple Phase III trials of novel antifibrotic and anti-inflammatory agents.